title: [Clinical pilot study on repeated use of heparin, vancomycin, colimycine locked flush solution for central intravenous implanted catheter in oncology].
abstract: With an anti-infectious and an antithrombotic prophylaxis aims, a locked flush solution including heparin and vancomycin, was used systematically for implantable venous access system for each patient, from january to april 1995. Since the 6th of april 1995, in order to widen the antibiotic spectrum on Gram negative bacteriae, we added colimycin at the flush solution. In 1995, 342 hospitalised patients held this type of venous access and received chemotherapy and/or radiochemotherapy for cancer. Two thousand six hundred thirty three manipulations were done, 575 with the first flush solution, 2058 with the second. During the year, 15 implantable access system (4.4%) were considered as infected, only 3 (0.9%) were removed, in the first period. THe infectious rate seemed to be stable, but the bacterial assessment to be modified between the two periods. The Gram negative bacterial infections seemed to decrease with colimycin addition (33% versus 50%). These results must be confirmed by a long term and/or randomized study.
authors.affiliation: Service de chirurgie générale et digestive, Hôpitaux de la Timone, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Guillet
authors.forename: B
authors.initials: B
authors.lastname: La Scola
authors.forename: D
authors.initials: D
authors.lastname: Bagarry-Liegey
authors.forename: K
authors.initials: K
authors.lastname: Lorvellec
authors.forename: N
authors.initials: N
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Nicoara
authors.forename: M
authors.initials: M
authors.lastname: Baciuchka
authors.forename: F
authors.initials: F
authors.lastname: Duffaud
authors.forename: P
authors.initials: P
authors.lastname: Carissimi
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: J
authors.initials: J
authors.lastname: Delorme
authors.forename: G
authors.initials: G
authors.lastname: Carle
authors.forename: D
authors.initials: D
authors.lastname: Braguer
authors.forename: F
authors.initials: F
authors.lastname: Quilichini
authors.forename: A
authors.initials: A
authors.lastname: Crevat
authors.forename: R
authors.initials: R
authors.lastname: Favre
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects; D003091:Colistin / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000209:etiology / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010865:Pilot Projects; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D014640:Vancomycin; D006493:Heparin; D003091:Colistin